BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Purely Proteins Limited And Inhibox Ltd. Launch Combined Drug Screening Programs


10/19/2005 5:11:00 PM

CAMBRIDGE, England, April 22 /PRNewswire/ -- Purely Proteins Ltd (Cambridge, UK) and Inhibox Ltd (Oxford, UK) today announced the launch of commercial drug discovery services based on their combined proprietary computational and laboratory-based screening technologies.

This platform is commencing with the immediate launch of discovery-ready drug screening programs for families of human phosphatases, kinases and proteases. Key members of these families, such as PTP-1B, c-abl and beta-secretase, are proven therapeutic targets in life-threatening diseases such as diabetes, cancer and Alzheimer's disease. Other therapeutic targets of immediate interest to clients can also be accessed on a fee-for-service basis.

The screening process involves the selection of highly specific virtual drugs against defined therapeutic targets from billions of putative starting compounds, using Inhibox's proprietary computational processes. The resulting highly selected compounds are synthesized and tested in Purely Proteins' comprehensive drug screening platforms. Experimental datasets are then made available for licensing either as new modules within Purely Proteins' existing relational database product TargetBASE, or as patented, early-stage licensing candidates.

TargetBASE already houses detailed structural, biochemical and pharmacological information about therapeutically relevant protein families. This new, experimentally exemplified chemical information will expand its content into the new field of chemical proteomics.

Commenting on the program, Purely Protein's Chief Executive Officer, Dr David Bailey, said, "We are delighted to be working with Inhibox, a company with extensive experience in computer-based drug screening and computational chemistry. The combination of Purely Proteins' expertise in purifying and assaying families of human proteins with the extreme power of Inhibox's computational screening will add significant value to both companies' products very rapidly."

Dr Paul Finn, Chief Executive Officer of Inhibox, said, "Purely Proteins is an ideal partner for Inhibox. Our technologies have been developed to exploit large-scale virtual screening opportunities such as those presented by the human proteome, which we can reduce to practice through Purely Proteins' extensive portfolio of discovery screens. Together, we can rapidly convert in silico designs into validated drug opportunities for new pharma and biotech clients. The collaboration with Purely Proteins is also an attractive mechanism for further progression of the results of the Internet-based Cancer Screensaver Initiative."

Purely Proteins

Purely Proteins (PP) has been established to exploit the increasing need for human proteins in pharmaceutical research. The company purifies suites of human proteins, as both drug targets and bio-therapeutics, using proprietary processes that ensure both high purity and biological activity. PP also offers drug-screening services, backed by state-of-the-art informatics, to examine therapeutic targeting to these proteins. More details about PP, its products, and its screening services can be found at http://www.purelyproteins.com/.

Inhibox

Inhibox, a recent spinout company from the Oxford University Chemistry Department, specializes in automated computational approaches for virtual screening of compounds, using its molecular database comprising 35 million commercial and combinatorial library compounds and high-throughput grid computing based hardware platforms. In addition Inhibox is developing novel docking algorithms and offers broader computational chemistry services. Inhibox is a partner in the Internet-based Cancer Screensaver Initiative (http://www.chem.ox.ac.uk/curecancer.html). Further information about Inhibox can be found at http://www.inhibox.com/.

Contacts Dr David Bailey Chief Executive Officer Purely Proteins 254 Cambridge Science Park Cambridge CB4 0WE United Kingdom Tel: +44 1223 426400 Fax: +44 1223 426003 Email: david.bailey@purelyproteins.com Web: http://www.purelyproteins.com/ Dr Paul Finn Chief Executive Officer Inhibox Ltd Central Chemistry Dept. South Parks Road Oxford OX1 3QH United Kingdom Tel: +44 01865 275424 Fax: +44 01865 275905 Email: paul.finn@inhibox.com Web: http://www.inhibox.com/

Purely Proteins Ltd

CONTACT: Dr David Bailey, Chief Executive Officer of Purely Proteins,+44-1223-426400, fax, +44-1223-426003, david.bailey@purelyproteins.com; orDr Paul Finn, Chief Executive Officer of Inhibox Ltd, +44-01865-275424, fax,+44-01865-275905, paul.finn@inhibox.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES